GB Sciences, Inc. focuses to be a technology and solution company that converts the cannabis plant into medicines, therapies, and treatments for various ailments. The company is developing technologies in plant biology, cultivation and extraction techniques, which are combined with biotechnology; and plans to produce medical-grade cannabis, cannabis concentrates, and cannabinoid therapies. GB Sciences, Inc. has an agreement with Growblox Sciences, Puerto Rico, LLC that grants the right to its technology and intellectual property. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryCannabis
SectorMedical
Phone+1-888-8953594
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees60
Next Earnings DateN/A
OptionableNot Optionable
GB Sciences (OTCMKTS:GBLX) Frequently Asked Questions
What is GB Sciences' stock symbol?
GB Sciences trades on the OTCMKTS under the ticker symbol "GBLX."
How were GB Sciences' earnings last quarter?
GB Sciences Inc (OTCMKTS:GBLX) posted its quarterly earnings data on Monday, November, 14th. The company reported ($0.04) earnings per share for the quarter. View GB Sciences' Earnings History.
Has GB Sciences been receiving favorable news coverage?
News headlines about GBLX stock have been trending somewhat positive this week, according to InfoTrie. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GB Sciences earned a media sentiment score of 1.4 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for GB Sciences.
Who are some of GB Sciences' key competitors?
Some companies that are related to GB Sciences include Abattis Bioceuticals (ATTBF), ABcann Global (ABCN), ABZENA/PAR VTG FPD 0.002 (ABZA), Almirall (LBTSF), Apotheca Biosciences (CBDC), Arno Therapeutics (ARNI), Axim Biotechnologies (AXIM), Biocure Technology (CURE), Canada House Wellness Group (CHV), Cannabics Pharmaceuticals (CNBX), CannaRoyalty (ORHOF), Cardiome Pharma (COM), China Longyi Group Int'l (CGYG), Creative Medical Technology (CELZ) and Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs (CYCCP).
What other stocks do shareholders of GB Sciences own?
Who are GB Sciences' key executives?
GB Sciences' management team includes the folowing people:
- Mr. John C. Poss, Chairman & CEO (Age 71)
- Ms. Ksenia Griswold, COO, CFO, VP & Controller (Age 36)
- Dr. Andrea Small-Howard M.B.A., Ph.D., MBA, Chief Science Officer & Director (Age 50)
- Mr. Krin Ellery Kuethe, Sr. VP of Cultivation (Age 35)
- Mr. John B. Davis, Gen. Counsel & Exec. VP
How do I buy shares of GB Sciences?
Shares of GBLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GB Sciences' stock price today?
One share of GBLX stock can currently be purchased for approximately $0.1430.
What is GB Sciences' official website?
How can I contact GB Sciences?
GB Sciences' mailing address is 6450 Cameron St Ste 110A, LAS VEGAS, NV 89118-4337, United States. The company can be reached via phone at +1-888-8953594.
MarketBeat Community Rating for GB Sciences (OTCMKTS GBLX)
MarketBeat's community ratings are surveys of what our community members think about GB Sciences and other stocks. Vote "Outperform" if you believe GBLX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GBLX will underperform the S&P 500 over the long term. You may vote once every thirty days.
